Is silodosin effective for the treatment of nocturia in men with benign prostatic hyperplasia?

This study aimed to investigate the safety and effectiveness of silodosin (Rapaflo, Silodyx) for the treatment of nocturia in men with benign prostatic hyperplasia (BPH). This study found that silodosin is safe and effective for the treatment of nocturia in these patients. 

People diagnosed with BPH (non-cancerous overgrowth of the prostate) or overactive bladder often experience lower urinary tract symptoms (LUTS). These can include nocturia (getting up to urinate during the night). Silodosin is a medication used to treat symptoms of BPH. The safety and effectiveness of silodosin for treating nocturia in men with BPH is still unclear. 

This study included 112 patients with BPH. They were treated with 8 mg of silodosin daily for 12 weeks. These patients kept a diary of how many times they urinated at night while on silodosin. They also completed questionnaires on BPH symptoms at the beginning of the study, at 4 and at 12 weeks. 

The number of nocturia episodes decreased at both 4 and 12 weeks of treatment. Patients also reported a quality of life improvement on questionnaires. Over 65% of patients reported a reduction of at least 25% in nocturia symptoms. 

11.8% of patients experienced side effects, but these were mild, such as dry mouth or itchy skin. The most common side effect was difficulty ejaculating in 7.6% of men.  

This study found that silodosin is safe and effective in the treatment of nocturia in men with BPH.

This study included a rather small number of patients. Also, there was no comparison group. Therefore, further studies are needed for more conclusive results.